Evidence map›Paper›PMID 35710428›Full record

ArticleTrials2022

Qatar Diabetes Mobile Application Trial (QDMAT): an open-label randomised controlled trial to examine the impact of using a mobile application to improve diabetes care in type 2 diabetes mellitus-a study protocol.

Noor Suleiman, Meis Alkasem, Zaina Al Amer, Obada Salameh, Noora Al-Thani, Mohammad Khair Hamad, Khaled Baagar, Ibrahem Abdalhakam, Manal Othman, Ragae Dughmosh and 6 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03998267 (Qatar Diabetes Mobile Application Trial), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03998267 naunknown statusnot on this map

Qatar Diabetes Mobile Application Trial

TypeinterventionalSponsorHamad Medical CorporationRan2019 to 2020Enrolled180ConditionsType2 Diabetes MellitusArmsDroobi, Standard of care
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Noor SuleimanQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar. noorsuleiman@gmail.com.ORCID http://orcid.org/0000-0002-0800-5629
Meis AlkasemQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
Zaina Al AmerDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Obada SalamehDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Noora Al-ThaniDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Mohammad Khair HamadDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Khaled BaagarDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Ibrahem AbdalhakamQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
Manal OthmanDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Ragae DughmoshDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Dabia Al-MohanadiDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Ali Al SanousiClinical Information Systems Department, Hamad Medical Corporation, Doha, Qatar.
Mohammed BashirDepartment of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar.
Odette ChagouryQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
Shahrad TaheriQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
Abdul-Badi Abou-SamraQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QAWeill Cornell Medical College in Qatar · QACornell University · US

Funding

Hamad Medical Corporation 17292/17
6 · The paper itself

Abstract

backgroundMobile health (mHealth) is increasingly advocated for diabetes management. It is unclear if mobile applications are effective in improving glycaemic control, clinical outcomes, quality of life and overall patient satisfaction in patients with type 2 diabetes (T2DM). A new mobile application was specifically built for people with T2DM with the help of the local expertise. The objective of the study was to evaluate the effectiveness of the mobile app.

methodsThe planned study is an ongoing open-label randomised controlled trial in which adults living with T2DM treated with insulin will be randomised 1:1 to the use of this diabetes application versus current standard care. The primary outcome will be the difference in mean HbA1c from baseline to 6 months. Other outcome measures include anthropometric measures, hypoglycaemic events, medication adjustments, number of clinical interactions and missed appointments and patient perceptions of their disease and diabetes self-management. The study will randomise 180 subjects for assessment of the primary outcome. DISCUSSION: We hypothesise that the diabetes-specific mobile application will improve glycaemic control, increase patient empowerment for self-management of diabetes and improve interaction between patients and healthcare providers. If the Qatar Diabetes Mobile Application Trial (QDMAT) demonstrates this, it will inform clinical services for the future self-management of T2DM.

trial registrationClinicalTrials.gov Identifier: NCT03998267 . Registered on 26 June 2019.

Indexed as

Diabetes Mellitus, Type 2Mobile ApplicationsSelf-ManagementAdultHumansQatarQuality of LifeRandomized Controlled Trials as TopicClinical trialLifestyle changeMobile healthSelf-managementType 2 diabetes mellitus

Identifiers

PMID35710428
PMCPMC9205079
OpenAlexW4283034114

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.